We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Optoelectrokinetic Tech Underlies New Biochip Approach

By LabMedica International staff writers
Posted on 05 Feb 2013
A recently developed optoelectrokinetic manipulation technique was used to separate microorganisms according to size, which demonstrated the potential of this method for the development of "lab-on-a-chip" diagnostic technologies.

The technique, rapid electrokinetic patterning - or REP, works by focusing an infrared laser to heat a fluid in a microchannel containing particles or bacteria. More...
An electric field is applied that combined with the laser's heating action causes the fluid to circulate in a "microfluidic vortex" that functions like a centrifuge to isolate particles based on size.

A detailed description of the method, which was used to collect three different types of microorganisms: the bacterium Shewanella oneidensis MR-1; the single-cell spherical fungus Saccharomyces cerevisiae; and the spherical bacterium Staphylococcus aureus, was published in the December 7, 2012, issue of the journal Lab on a Chip.

Senior author Dr. Steven T. Wereley, professor of mechanical engineering at Purdue University (West Lafayette, IN, USA), said, "By properly choosing the electrical frequency we can separate blood components, such as platelets. Say you want to collect Shewanella bacteria, so you use a certain electrical frequency and collect them. Then the next day you want to collect platelets from blood. That is going to be a different frequency. We foresee the ability to dynamically select what you will collect, which you could not do with conventional tools. The new results demonstrate that REP can be used to sort biological particles but also that the technique is a powerful tool for development of a high-performance on-chip bioassay system."

"It will not be on the market in a year," said Dr. Wereley. "We are still in the research end of this. We are sort of at the stage of looking for the killer app for this technology."

The REP method may also have applications in the field of nanomanufacturing due to its ability to assemble suspensions of particles known as colloids. This may be particularly relevant to the pharmaceutical industry, as a number of drugs are manufactured from solid particles suspended in liquid. Currently particles are collected and separated from the liquid by a process of filtration and centrifugation—methods not now available for production use at the nano level.

Related Links:

Purdue University



New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
POC Immunoassay Analyzer
Procise DX
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.